Blocking antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1/PD-L1 immune checkpoints have shown durable clinical responses in a variety of cancers, including cervical cancer (12–14). Here, CTLA4 is linked to cancer.